Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2018
Reporting Period: Third quarter ended September 30, 2018
Context: This filing announces the issuance of a press release regarding financial results for the third quarter of 2018. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the 8-K filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided.
Material Changes
The filing text does not provide specific data on material changes versus the prior comparable period. It only confirms that results for the third quarter ended September 30, 2018, have been released.
Guidance, Outlook, and Risks
- Conference Call: Management scheduled a conference call for November 7, 2018, at 9:00 a.m. Eastern Time to present financial results.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: Investors are directed to Item 1A ("Risk Factors") in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, for a detailed discussion of risks.
- Legal Disclaimer: Information in Item 2.02 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2018 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check the Form 10-K (filed March 1, 2018) and Form 10-Q (filed May 10, 2018) for updated risk factors referenced in this filing.
- Confirm the date and access details for the archived webcast of the November 7, 2018, conference call.